AKT1 and colorectal carcinoma: This is an interesting finding in the context of PIK3CA-mutated CRC because mTORC1 is a downstream target of PI3K-Akt by inhibiting TSC1/2 (see Fig. 2) and because there is evidence for aspirin-mediated direct acetylation and inactivation of mTOR and the mTORC1 complex [130, 240].